Evogene Ltd. — Form SCHEDULE 13D/A
Filed September 11, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 42/100
What the filing says
Kfir Silberman (via L.I.A Pure Capital Ltd.) and Eli Zamir (via Invest-Pro Shukai Hon Ltd.) announced on September 8, 2026, intent to launch a special tender offer under Israeli Companies Law Section 328 to acquire sufficient ordinary shares to hold ≥25% of Evogene's voting rights, at an offer price of ≥$0.55 per share. The reporting persons cited concerns about the conduct of the company's recent annual shareholder meeting, alleged violations of law and internal policy, and fairness issues, and reserved rights to challenge the board election. Formal offer documents would follow within days; final share count needed for offer calculation.
Why this rating
Activist challenge to board control and governance; material if stake is significant, but absent company market cap and share count, magnitude unclear relative to size.
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.